Belinostat
- Generic Name
- Belinostat
- Brand Names
- Beleodaq
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N2O4S
- CAS Number
- 866323-14-0
- Unique Ingredient Identifier
- F4H96P17NZ
- Background
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...
- Indication
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .
- Associated Conditions
- Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.